Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHS552 in Type 1 Diabetes Mellitus
NCT05272059Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Biologic
01
Overview
Phase 1, randomised, double-blind trial of MHS552 in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Novartis. Primary endpoint: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs) up to 20 weeks. Planned start Sep 2023; status: withdrawn.
02
Drugs
MHS552
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05272059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272059.